Dermorphin vs Low-Dose Naltrexone (LDN)
A side-by-side research comparison of Dermorphin and Low-Dose Naltrexone (LDN) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dermorphin | Low-Dose Naltrexone (LDN) |
|---|---|---|
| Full name | Dermorphin (Opioid Heptapeptide) | Low-Dose Naltrexone |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound | Off-label prescription |
| Mechanism | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. | Brief nocturnal opioid receptor blockade triggers compensatory upregulation of endogenous opioid production and OGF (opioid growth factor), modulating immune cell proliferation and reducing inflammatory cytokines. |
| Molecular weight | 803.9 Da | 341.40 Da |
| Half-life | Short (peptide) | ~4 hours |
| Bioavailability | Injection (research) | ~5-40% oral (first-pass) |
| Typical dose | Not established for human use | 1.5-4.5 mg |
| Frequency | Research only | Nightly at bedtime |
| Route | Injection (research) | Oral capsule (compounded) |
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
Low-Dose Naltrexone (LDN) reported benefits
- Immune modulation
- Reduced inflammation
- Chronic pain relief
- Autoimmune support
- Improved mood via endorphins
- Weight loss support
Related comparisons
Research and educational reference only. Not medical advice.